GeoVax Labs, Inc. (GOVX)
| Market Cap | 3.70M -76.1% |
| Revenue (ttm) | 852,282 -84.8% |
| Net Income | -21.37M |
| EPS | -15.94 |
| Shares Out | 2.89M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 536,590 |
| Open | 1.320 |
| Previous Close | 1.340 |
| Day's Range | 1.220 - 1.500 |
| 52-Week Range | 0.963 - 34.750 |
| Beta | 3.63 |
| Analysts | Strong Buy |
| Price Target | 10.00 (+681.25%) |
| Earnings Date | Jul 27, 2026 |
About GOVX
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. It develops GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine.... [Read more]
Financial Performance
In 2025, GeoVax Labs's revenue was $2.49 million, a decrease of -37.06% compared to the previous year's $3.95 million. Losses were -$21.46 million, -14.11% less than in 2024.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for GOVX stock is "Strong Buy." The 12-month stock price target is $10.0, which is an increase of 681.25% from the latest price.
News
GeoVax Labs Transcript: Investor update
GEO-MVA, an MVA-based vaccine for Mpox and smallpox, is advancing to a pivotal phase III trial with an expedited EMA pathway, targeting a $2 billion market with significant unmet demand. Recent funding strengthens the balance sheet, and scalable manufacturing is planned to meet global needs.
GeoVax Labs discontinues development of COVID-19 vaccine candidate
GeoVax Labs (GOVX) announced earlier today a strategic prioritization of its development portfolio to concentrate resources on its lead programs, GEO-MVA and Gedeptin. As part of this decision, the co...
Roth Capital ‘strongly’ agrees with GeoVax ending COVID-19 development
After GeoVax Labs (GOVX) decided to discontinue development of its GEO-CM04S1 COVID-19 vaccine, Roth Capital “strongly” agrees with this decision, noting that it was not due to any safety or…
GeoVax Labs files to sell 7.64M shares of common stock for holders
09:03 EDT GeoVax Labs (GOVX) files to sell 7.64M shares of common stock for holders
GeoVax Labs Registration statement: Registration filing
GeoVax Labs filed a registration statement on May 26, 2026, providing details about a securities offering with the SEC.
3 Penny Stocks to Watch Now, 5/19/26
GeoVax Labs ($GOVX), Roboai ($AIIO), and Sunshine Biopharma ($SBFM) are the three penny stocks to watch on May 19, according to TipRanks’ Penny Stock Screener tool. Penny stocks refer to…
GeoVax Labs Proxy statement: Proxy filing
GeoVax Labs filed a proxy statement on May 18, 2026, providing details for shareholder voting and corporate governance matters.
GeoVax Labs Quarterly report: Q1 2026
GeoVax Labs has published its Q1 2026 quarterly earnings report on May 14, 2026.
GeoVax Labs Earnings release: Q1 2026
GeoVax Labs released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
GeoVax Labs Proxy statement: Proxy filing
GeoVax Labs filed a proxy statement on May 8, 2026, providing details for shareholder voting and corporate governance matters.
GeoVax Labs Proxy statement: Proxy filing
GeoVax Labs filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
GeoVax Labs price target lowered to $10 from $14 at Roth Capital
Roth Capital lowered the firm’s price target on GeoVax Labs (GOVX) to $10 from $14 and keeps a Buy rating on the shares. GeoVax ended Q4 with limited cash and…
GeoVax Labs Registration statement: Registration filing
GeoVax Labs filed a registration statement on April 16, 2026, providing details about a securities offering with the SEC.
GeoVax Labs Registration statement: Registration filing
GeoVax Labs filed a registration statement on April 16, 2026, providing details about a securities offering with the SEC.
GeoVax Labs Proxy statement: Proxy filing
GeoVax Labs filed a proxy statement on April 16, 2026, providing details for shareholder voting and corporate governance matters.
GeoVax Labs files to sell 1.27M shares of common stock for holders
06:04 EDT GeoVax Labs (GOVX) files to sell 1.27M shares of common stock for holders
GeoVax Labs files to sell 865,804 shares of common stock for holders
06:05 EDT GeoVax Labs (GOVX) files to sell 865,804 shares of common stock for holders
GeoVax Labs Annual report: Q4 2025
GeoVax Labs has published its Q4 2025 annual report on April 15, 2026.
GeoVax Labs Earnings release: Q4 2025
GeoVax Labs released its Q4 2025 earnings on April 15, 2026, summarizing the period's financial results.
GeoVax Labs downgraded to Hold from Buy at D. Boral Capital
D. Boral Capital analyst Jason Kolbert downgraded GeoVax Labs (GOVX) to Hold from Buy without a price target The firm says the company is facing a “more constrained” near-term outlook…
GeoVax Labs Transcript: Biotech Showcase 2026
Multiple clinical-stage programs are advancing, with GEO-MVA set for a phase III trial and aiming to address global vaccine shortages. Manufacturing innovations and strategic partnerships are expected to accelerate commercialization, while financial strategy focuses on non-dilutive funding and expedited regulatory pathways.
Geovax Labs Inc trading halted, news pending
19:50 EST Geovax Labs (GOVX) Inc trading halted, news pending
GeoVax Labs files to sell 18.29M units
Roth Capital Partners is acting as placement agent in connection with this offering.
GeoVax Labs Registration statement: Registration Filing
GeoVax Labs filed a registration statement on December 12, 2025, providing details about a securities offering with the SEC.
GeoVax Labs Earnings Call Transcript: Q3 2025
GEO-MVA received expedited EMA guidance, enabling a direct phase III trial and accelerating market entry. Revenue declined due to BARDA contract termination, while R&D expenses fell and cash reserves remain tight. Strategic partnerships and manufacturing scale-up are key priorities.